Barclays PLC Increases Holdings in Compass Therapeutics, Inc. (NASDAQ:CMPX)

Barclays PLC increased its stake in shares of Compass Therapeutics, Inc. (NASDAQ:CMPX) by 195.4% during the third quarter, according to its most recent filing with the SEC. The institutional investor owned 170,245 shares of the company’s stock after purchasing an additional 112,614 shares during the period. Barclays PLC owned 0.12% of Compass Therapeutics worth $314,000 as of its most recent SEC filing.

Several other large investors have also added to or reduced their stakes in the stock. Bank of New York Mellon Corp boosted its position in shares of Compass Therapeutics by 12.4% in the second quarter. Bank of New York Mellon Corp now owns 283,938 shares of the company’s stock valued at $284,000 after acquiring an additional 31,433 shares during the period. Renaissance Technologies LLC boosted its holdings in Compass Therapeutics by 99.7% in the 2nd quarter. Renaissance Technologies LLC now owns 140,600 shares of the company’s stock valued at $141,000 after purchasing an additional 70,200 shares during the period. Rhumbline Advisers grew its position in shares of Compass Therapeutics by 10.3% during the 2nd quarter. Rhumbline Advisers now owns 131,789 shares of the company’s stock valued at $132,000 after purchasing an additional 12,315 shares in the last quarter. Ground Swell Capital LLC bought a new position in shares of Compass Therapeutics in the second quarter worth $124,000. Finally, The Manufacturers Life Insurance Company purchased a new stake in shares of Compass Therapeutics in the third quarter worth $79,000. Institutional investors own 68.43% of the company’s stock.

Compass Therapeutics Stock Performance

CMPX stock opened at $1.56 on Friday. The firm has a market cap of $214.64 million, a P/E ratio of -4.22 and a beta of 0.89. The firm’s fifty day moving average is $1.57 and its 200 day moving average is $1.43. Compass Therapeutics, Inc. has a 52 week low of $0.77 and a 52 week high of $2.34.

Compass Therapeutics (NASDAQ:CMPX) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.08) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.03. As a group, analysts forecast that Compass Therapeutics, Inc. will post -0.35 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on CMPX. HC Wainwright restated a “buy” rating and issued a $10.00 target price on shares of Compass Therapeutics in a research note on Monday, November 11th. Leerink Partners cut shares of Compass Therapeutics from an “outperform” rating to a “market perform” rating and decreased their price objective for the stock from $5.00 to $4.00 in a research report on Friday, November 15th. LADENBURG THALM/SH SH upgraded shares of Compass Therapeutics from a “neutral” rating to a “buy” rating and set a $5.00 target price for the company in a research report on Monday, September 16th. Leerink Partnrs lowered shares of Compass Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Friday, November 15th. Finally, D. Boral Capital started coverage on shares of Compass Therapeutics in a report on Monday, December 23rd. They set a “buy” rating and a $32.00 price objective for the company. Two analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $11.80.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.